Department of Urology, Graduate School of Medicine, Ehime University.
Acta Med Okayama. 2021 Jun;75(3):345-349. doi: 10.18926/AMO/62229.
The management of blood pressure is a significant concern for surgeons and anesthesiologists performing adrenalectomy for pheochromocytoma. We evaluated clinical factors in pheochromocytoma patients to identify the predictors of postoperative hypotension. The medical records of patients who underwent adrenalectomy for pheochromocytoma between 2001 and 2017 were retrospectively reviewed and clinical and biochemical data were evaluated. Of 29 patients, 13 patients needed catecholamine support in the perisurgical period while 16 patients did not. There were significant differences in median age, tumor size, and blood pressure drop (maxmin) between the 2 groups (68 vs 53 years old, p=0.045; 50 vs 32 mm diameter, p=0.022; 110 vs 71 mmHg, p=0.015 respectively). In univariate logistic analysis, age > 65.5 years, tumor size > 34.5 mm, urine metanephrine > 0.205 mg/day and urine normetanephrine > 0.665 mg/day were significant predictors of prolonged hypotension requiring postoperative catecholamine support. Tumor size and urine metanephrine and urine normetanephrine levels were correlated with postoperative hypotension. These predictors may help in the safe perioperative management of pheochromocytoma patients treated with adrenalectomy.
血压管理是行肾上腺切除术的外科医生和麻醉师关注的重点,因为此类手术可能导致嗜铬细胞瘤患者术后低血压。我们评估了嗜铬细胞瘤患者的临床因素,以确定术后低血压的预测因素。回顾性分析了 2001 年至 2017 年间行肾上腺切除术的嗜铬细胞瘤患者的病历,并评估了临床和生化数据。在 29 例患者中,13 例患者在围手术期需要儿茶酚胺支持,而 16 例患者不需要。两组患者的中位年龄、肿瘤大小和血压下降幅度(最大值-最小值)存在显著差异(68 岁比 53 岁,p=0.045;50 毫米比 32 毫米直径,p=0.022;110 毫米汞柱比 71 毫米汞柱,p=0.015)。单因素逻辑分析显示,年龄>65.5 岁、肿瘤直径>34.5 毫米、尿甲氧基肾上腺素>0.205 毫克/天和尿去甲肾上腺素>0.665 毫克/天是术后需要儿茶酚胺支持以延长低血压的显著预测因素。肿瘤大小以及尿甲氧基肾上腺素和尿去甲肾上腺素水平与术后低血压相关。这些预测因素可能有助于安全地围手术期管理接受肾上腺切除术的嗜铬细胞瘤患者。